Whitehouse_1994_Clin.Geriatr.Med_10_339

Pharmacotherapy that is effective for AD is a major goal of extensive research programs throughout the world. With the approval of tacrine in the United States, an agent is now available that has demonstrated improvement in cognition for some AD patients. Other similar symptomatic therapies are likely to become available in the near future. In the long term, prevention and cure will be based on understanding pathogenesis, such as the genetic defects that can lead to disease in some families.